Teladoc (TDOC) AI Stock Analysis

• Market Cap: $1.33B
• Dividend Yield: N/A
• Average Volume (3M): 5.98M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.35
• Revenue Growth: -2.54%
• EPS Growth: -322.03%
• Country: US
• Employees: 4,620
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Healthcare Information Services
• EPS (TTM): -0.53
• Shares Outstanding: 175,434,770
• 10 Day Avg. Volume: 9,043,311
• 30 Day Avg. Volume: 5,976,773
• PEG Ratio: >-0.01
• Price to Book (P/B): 1.65
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 231.03
• Enterprise Value/Market Cap: 3.37
• Enterprise Value/Revenue: 0.43
• Enterprise Value/Gross Profit: 2.63
• Enterprise Value/Ebitda: -1.82
• 1Y Price Target: $8.46
• Price Target Upside: 0.59% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 16

• Rating: 54 Neutral
• Price Target: $8.00 ▼(-4.88%Downside)

Teladoc's overall stock score reflects significant profitability challenges and valuation concerns, with some positive aspects in cash flow and strategic growth initiatives. Technical analysis suggests a cautious approach, with the stock underperforming long-term averages. The earnings call highlighted both strategic opportunities and hurdles, making it crucial to monitor future developments closely.

Positive Factors

Acquisition and Market Expansion

The acquisition of UpLift provides a solid pathway for in-network coverage in the BetterHelp segment, potentially offering affordability in an uncertain economic climate.

Financial Performance

Consolidated revenue and adjusted EBITDA both exceeded analyst and consensus estimates, with notable outperformance in the Integrated Care segment.

Membership Growth

Integrated Care membership grew nicely, up 12% to over 102.5MM members, representing potential cross-and upsell opportunities.

Negative Factors

Enrollment Decline

Teladoc expects chronic care enrollment in the second quarter to decline sequentially due to a previously discussed contract loss.

Investment and Margin Pressure

The company will need to invest additional capital to optimize care delivery which could drive weaker near-term margins.

Revenue Decrease

Average revenue per US Integrated Care Member fell 8.6% sequentially and 8.0% year-over-year, which could impact overall revenue growth.

Teladoc Business Overview & Revenue Model

Company Description

Teladoc Health, Inc. provides virtual healthcare services in the United States and internationally. The company offers a portfolio of services and solutions covering non-urgent, episodic, chronic, and complicated medical conditions, including diabetes, hypertension, chronic kidney disease, cancer, congestive heart failure, and mental health conditions. It offers a range of programs and services, including primary and specialty care telehealth solutions, chronic condition management, expert medical services, mental health solutions, and platform and program services. The company serves employers, health plans, hospitals and health systems, and insurance and financial services companies, as well as individual members. It offers its products and services under the Teladoc, Livongo, and BetterHelp brands. The company was formerly known as Teladoc, Inc. and changed its name to Teladoc Health, Inc. in August 2018. The company was incorporated in 2002 and is headquartered in Purchase, New York.

How the Company Makes Money

Teladoc generates revenue through a combination of subscription fees and visit fees. Subscription fees are primarily derived from contracts with employers, health plans, and insurance providers, who pay Teladoc to offer its services to their members or employees. These contracts are typically based on a per-member-per-month fee structure. Additionally, Teladoc earns visit fees each time a member uses its services for a medical consultation. The company also benefits from strategic partnerships with healthcare providers and insurers, which expand its reach and increase its client base. Other revenue streams include licensing its technology platform to other healthcare providers and offering specialty services that cater to specific medical needs.

Teladoc Financial Statement Overview

Summary

Teladoc's financials reveal challenges with profitability and leverage but show potential in cash flow improvements. Revenue growth is inconsistent, and profitability metrics are under pressure. However, a stable equity base and positive free cash flow are notable strengths.

Income Statement

Teladoc has shown fluctuating revenue growth, with a decline from 2023 to the TTM period. The gross profit margin is stable at around 66-67%, but the net profit margin remains negative, indicating ongoing losses. EBIT and EBITDA margins are also negative, reflecting operational challenges.

Balance Sheet

The debt-to-equity ratio is relatively high, suggesting considerable leverage, but the equity ratio demonstrates a stable equity base. The ROE remains negative due to continuous net losses, which indicates profitability concerns.

Cash Flow

Free cash flow has been positive in the TTM period, showing signs of improvement. The operating cash flow to net income ratio is favorable, suggesting a good cash conversion from operations despite negative net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.55B	2.57B	2.60B	2.41B	2.03B	1.09B
Gross Profit	1.70B	1.82B	1.84B	1.66B	1.38B	703.13M
EBITDA	-734.57M	-587.01M	154.00M	-13.38B	-84.67M	-438.01M
Net Income	-1.01B	-1.00B	-220.37M	-13.66B	-428.79M	-485.14M
Balance Sheet
Total Assets	3.44B	3.52B	4.39B	4.35B	17.73B	17.76B
Cash, Cash Equivalents and Short-Term Investments	1.19B	1.30B	1.12B	918.18M	896.02M	786.57M
Total Debt	1.59B	1.58B	1.59B	1.57B	1.27B	1.47B
Total Liabilities	2.02B	2.03B	2.07B	2.04B	1.69B	1.87B
Stockholders Equity	1.43B	1.49B	2.33B	2.31B	16.05B	15.88B
Cash Flow
Free Cash Flow	209.41M	282.89M	193.67M	16.53M	130.06M	-79.55M
Operating Cash Flow	300.68M	293.68M	350.02M	189.29M	193.99M	-53.51M
Investing Cash Flow	-211.81M	-124.05M	-156.35M	-167.74M	-72.98M	-590.98M
Financing Cash Flow	7.33M	8.31M	10.85M	6.50M	40.95M	859.14M

Teladoc Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.41
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TDOC, the sentiment is Positive. The current price of 8.41 is above the 20-day moving average (MA) of 7.32, above the 50-day MA of 7.18, and below the 200-day MA of 8.96, indicating a neutral trend. The MACD of 0.20 indicates Negative momentum. The RSI at 65.93 is Neutral, neither overbought nor oversold. The STOCH value of 72.02 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TDOC.

Teladoc Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NHC	78 Outperform	$1.67B	15.58	11.19%	2.24%	19.16%	31.92%
PHR	71 Outperform	$1.64B	―	-15.97%	―	16.29%	66.01%
SDGR	59 Neutral	$1.51B	―	-43.33%	―	22.29%	-32.89%
TDOC	54 Neutral	$1.33B	―	-54.49%	―	-2.54%	-322.03%
Sector *	51 Neutral	$7.41B	0.36	-61.88%	2.34%	16.99%	1.69%
ARQT	51 Neutral	$1.64B	―	-70.58%	―	100.03%	64.22%
ELVN	36 Underperform	$1.27B	―	-31.30%	―	―	12.85%

Teladoc Corporate Events

Teladoc Approves Key Proposals at Annual Meeting

On May 22, 2025, Teladoc Health, Inc. held its Annual Meeting of Stockholders, where several key proposals were approved. Notably, the stockholders approved an amendment to the 2023 Incentive Award Plan, increasing the number of shares available for issuance by 6,850,000. Additionally, the election of directors and the ratification of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025, were confirmed. These decisions are expected to impact the company’s strategic direction and operational governance.

The most recent analyst rating on (TDOC) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Teladoc stock, see the TDOC Stock Forecast page.